307. Canavan disease
3 clinical trials, 5 drugs (DrugBank: 1 drug), 0 gene, 0 pathway
Searched query = "Canavan disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00657748 (ClinicalTrials.gov) | September 2009 | 9/4/2008 | Lithium and Acetate for Canavan Disease | Evaluation of the Tolerance and Efficiency of a Combined Oral Therapy With Lithium and GTA in Patients With Canavan Disease | Canavan Disease;Infantile;Deficiency Disease;Aspartoacylase;Leukodystrophy, Spongiform | Drug: Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug) | Assistance Publique - Hôpitaux de Paris | European Leukodystrophy Association;European Leukodystrophy Association | Withdrawn | 1 Year | 15 Years | Both | 0 | Phase 2 | France |
| 2 | NCT00724802 (ClinicalTrials.gov) | March 2008 | 18/6/2008 | Oral Glyceryl Triacetate (GTA) in Newborns With Canavan | Oral Glyceryl Triacetate (GTA) in Newborns With Canavan | Canavan Disease | Dietary Supplement: GTA (Glyceryl triacetate);Drug: GTA glyceryl triacetate | Shaare Zedek Medical Center | NULL | Recruiting | N/A | 18 Months | Both | 1 | N/A | Israel |
| 3 | NCT00278707 (ClinicalTrials.gov) | January 2006 | 15/1/2006 | GTA-Glyceryltriacetate for Canavan Disease | Phase 1 Treatment With GTA in Two Infant With Canavan Disease | Infantile Canavan Disease;Deficiency Disease, Aspartoacylase | Drug: GTA: Glyceryltriacetate | Sheba Medical Center | NULL | Active, not recruiting | N/A | 15 Months | Both | 5 | Phase 1 | Israel |